Phaxiam Therapeutics says it has notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (ADSs) representing its ordinary shares, which should be effective before the market opens on March 11.

Its ordinary shares have been listed on Euronext Paris since May 2013, initially under the name Erytech Pharma. The company listed its ADSs on the Nasdaq Global Select Market in November 2017, then transferred their listing to the Nasdaq Capital Market in April 2023.

'This delisting will enable us to save valuable resources and refocus our optimized organization on key development programs, while maintaining our presence on Euronext Paris', explains its CFO Eric Soyer.

Copyright (c) 2024 All rights reserved.